title: Application of growth factor stimulants improves cytogenetic analysis of chronic myeloproliferative disorder patients without alteration to cell lineage or clonality.
abstract: Conventional cytogenetic methods rely on culturing bone marrow aspirates to obtain suitable and sufficient mitotic figures for G-banded analysis. Samples from patients with chronic myeloproliferative disorders (CMPD) often have increased failure rates due to reduced growth and poor morphology, all of which hamper the conventional karyotyping investigation. The application of growth factor (GF) stimulants to bone marrow aspirates has been shown to yield significant increases in both the quality and quantity of bone marrow metaphases obtained in 53 CPMD patient samples. All cultures were stimulated using the conditioned supernatant from the human bladder carcinoma cell line 5637, which contains IL-3, IL-6, and G-CSF. Results were assessed qualitatively on G-banded preparations and quantitatively by mitotic index (MI = % dividing cells). To assess whether the application of GF stimulants leads to clonal selection, culture samples from 15 patients were analyzed by fluorescence in situ hybridization, which supported the theory that clonal selection remains unaltered in GF-stimulated cultures. In addition to this immunophenotyping of cells, we demonstrated the lineage of cells propagated under these conditions. Cell markers were chosen to characterize B-lymphoid, T-lymphoid, myeloid, and primitive cell types. Results indicated that T cells were maintained in culture and B-lymphoid markers remained negative. In the myeloid subset, there was an overall reduction in the pan-myeloid markers. We believe this represents the loss of terminally differentiated cells (e.g., neutrophils) in culture. Overall, the study clearly demonstrates that the application of GF stimulants does not alter clonality or cell lineage propagated in these samples and is therefore suitable for application in diagnostic cytogenetic laboratories.
authors.affiliation: Department of Academic Haematology, Royal Free and University College London Medical School, Rowland Hill Street, London, NW3 2PF, United Kingdom. b.vaughan@medsch.ucl.ac.uk
authors.forename: B R
authors.initials: BR
authors.lastname: Vaughan
authors.forename: M A
authors.initials: MA
authors.lastname: Scott
authors.forename: J D
authors.initials: JD
authors.lastname: Howard
authors.forename: E P
authors.initials: EP
authors.lastname: Nacheva
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019070:Cell Lineage; D002908:Chronic Disease; D002999:Clone Cells; D020732:Cytogenetic Analysis; D005260:Female; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000235:genetics*; D014407:Tumor Cells, Cultured
chemical_list: D006133:Growth Substances